Latest Articles | Contact

Home


Editorial Board


Recent Articles


Submit to this journal


Special Issues


Current issue



 Research Article 


Download PDF



View full article


Published Date
November 30, 2016

Vol. 3, Issue 8

Cancer Antigen 125 Levels can be Used as a Tumor Marker for Monitoring Patients with Endometrial Serous Carcinoma?

MW Hegazy, Wael H Elsawy, A Tolba and M Shoukri

Corresponding author: Mohamed W Hegazy, Department of Radiation Oncology, King Faisal Specialist Hospital & Research Center, Kingdom of Saudi Arabia, PO Box 3354, Riyadh 11211 MBC 64, Saudi Arabia

Endometrial adenocarcinoma is the most common type of uterine cancer. Endometrial cancer is classified into two subtypes (I and II), which reflect general characteristics of its clinicopathological spectrum. Uterine serous adenocarcinoma (USAC) is under Type II neoplasms which are associated with more aggressive behavior than type I tumors. While they comprise 10-20% of endometrial carcinomas, they account for 40% of deaths from the disease.

Citation: Hegazy MW, Elsawy WH, Tolba A, Shoukri M (2016) Cancer Antigen 125 Levels can be Used as a Tumor Marker for Monitoring Patients with Endometrial Serous Carcinoma?. Int J Cancer Clin Res 3:075.



 Clinical Image 


Download PDF



View full article


Published Date
November 26, 2016

Vol. 3, Issue 8

Massive Arterial Bleeding after Lenvatinib Therapy for Thyroid Cancer

Koichi Suyama, DaizoMurakami, Saori Fujiwara, Takashi Takeshita, Aiko Sueta, ToukoInao, Mutsuko Yamamoto-Ibusuki, Yutaka Yamamoto, Shin-yaShiraishi and Hirotaka Iwase

Corresponding author: Koichi Suyama, Kumamoto University Hospital Cancer Center, Graduate School of Life Sciences, Kumamoto University, 1-1-1, Honjyo, Chuo-ku, Kumamoto-city, 860-8556, Kumamoto, Japan

A 69-year-old woman presented with hoarseness and other symptoms of laryngeal stenosis. A palpably large tumorin her neck was shown by computed tomography (CT) to expand invasively from her upper left thyroid lobe, and to involve her left common carotid artery and internal jugular vein (Figure 1 A-1). The diagnosis of papillary thyroid cancer was based on cytological evidence from fine needle aspiration biopsy.

Citation: Suyama K, Murakami D, Fujiwara S, Takeshita T, Sueta A, et al. (2016) Massive Arterial Bleeding after Lenvatinib Therapy for Thyroid Cancer. Int J Cancer Clin Res 3:074.



 Short Review 


Download PDF



View full article


Published Date
November 26, 2016

Vol. 3, Issue 8

Pigmented Paget Disease of the Nipple: A Rare Breast Cancer Presentation

Santiago Sherwell-Cabello, Antonio Maffuz-Aziz, Silvia Natalia Lopez-Hernandez, Melissa Lizeth Flores-Cortes, Veronica Bautista-Pina and Sergio Rodriguez-Cuevas

Corresponding author: Santiago Sherwell-Cabello, Instituto de Enfermedades de la Mama, FUCAM AC, Bordo 100, StaUrsula Coapa, Coyoacan 04980, Mexico City, Mexico

Institutional board approval was obtained before commencement of this study. A retrospective study was conducted in all women diagnosed with breast cancer at our institution from January 2005 to December 2013. Standard immunohistochemical breast cancer panel was performed to all patients (ER, PR, Her-2 and Ki-67) and CK-7, P63 and S-100 when the pigmented variety was presented. Patients with pigmented Paget disease were selected and demographic characteristics were established.

Citation: Sherwell-Cabello S, Maffuz-Aziz A, Lopez-Hernandez SN, Flores-Cortes ML, Bautista-Pina V, et al. (2016) Pigmented Paget Disease of the Nipple: A Rare Breast Cancer Presentation. Int J Cancer Clin Res 3:073.



 Review Article 


Download PDF



View full article


Published Date
November 19, 2016

Vol. 3, Issue 8

Colorectal Cancer Aggressiveness is Related to Fibronectin Over Expression, Driving the Activation of SDF-1:CXCR4 Axis

Sofia Gouveia-Fernandes, Tania Carvalho, Germana Domingues, Renata Bordeira-Carrico, Sergio Dias and Jacinta Serpa

Corresponding author: Jacinta Serpa, Centro de Estudos de Doencas Cronicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa Campo Martires da Patria 130, 1169-056 Lisbon, Portugal

Cancer hallmarks result from dynamical interactions between tumor cells and tumor microenvironment, including normal cells, growth factors and extracellular matrix (ECM) components. Fibronectin (FN) is a high molecular weight, multidomain glycoprotein, present as a soluble form in body fluids, such as plasma (plasma FN), and as an insoluble form in ECM (cellular FN).

Citation: Gouveia-Fernandes S, Carvalho T, Domingues G, Bordeira-Carrrico R, Sergio Dias, et al. (2016) Colorectal Cancer Aggressiveness is Related to Fibronectin Over Expression, Driving the Activation of SDF-1:CXCR4 Axis. Int J Cancer Clin Res 3:072.



 Case Report 


Download PDF



View full article


Published Date
November 16, 2016

Vol. 3, Issue 8

Prolonged Use of Aprepitant in Metastatic Breast Cancer and a Reduction in CA153 Tumour Marker Levels

Mark Lee, Matthew McCloskey and Stephanie Staples

Corresponding author: Mark Lee, St Benedict's Hospice, St Benedict's Way, Ryhope, Sunderland SR2 0NY, UK

Nausea and vomiting are common problems in patients with advanced cancer. This case report describes a patient whose refractory nausea and vomiting improved significantly with the use of Aprepitant, a highly selective neurokinin 1 receptor antagonist. This improvement led to prolonged daily administration, during which time no chemotherapy or hormone therapy was administered. CA153 tumour markers were noted to have fallen during administration.

Citation: Lee M, McCloskey M, Staples S (2016) Prolonged Use of Aprepitant in Metastatic Breast Cancer and a Reduction in CA153 Tumour Marker Levels. Int J Cancer Clin Res 3:071.



 Research Article 


Download PDF



View full article


Published Date
October 22, 2016

Vol. 3, Issue 7

Validation of Measurement Based Dose Volume Metrics for the Quality Assurance of VMAT Plans

Sankar Arumugam, Aitang Xing, Tony Young, David Thwaites and Lois Holloway

Corresponding author: Sankar Arumugam, Department of Radiation Oncology, Cancer Therapy Centre, Liverpool Hospital, Sydney, NSW 2170, Australia

Ten each of prostate and head and neck (H&N) VMAT plans were considered for this study. Three types of errors were introduced into the original plans: gantry angle independent and dependent MLC errors, and gantry angle dependent dose error. The percentage difference in PTV-D95 between TPS and 3DVH was compared for no-error and error introduced plans.

Citation: Arumugam S, Xing A, Young T, Thwaites D, Holloway L (2016) Validation of Measurement Based Dose Volume Metrics for the Quality Assurance of VMAT Plans. Int J Cancer Clin Res 3:070.



 Case Report 


Download PDF



View full article


Published Date
October 19, 2016

Vol. 3, Issue 7

A First Case of Male Breast Cancer Responding to Combined Aromatase Inhibitor/Palbociclib Therapy

Steven Sorscher

Corresponding author: Steven Sorscher, MD, Professor of Medicine, Department of Oncology, Wake Forest Medical School, Medical Center Blvd, Winston-Salem, NC 27104, USA

For men with metastatic breast adenocarcinoma standard therapies typically involve the same therapies used for woman. Recently the FDA approved the aromatase inhibitor letrozole combined with the inhibitor of cyclin dependent kinase 4/6 (CDK4/6) palbociclib as first line therapy for women with metastatic breast cancer. Here we report a first case of a man with metastatic breast cancer whose tumor responded to palbociclib and letrozole. This combination might be effective for other men with metastatic breast cancer as well.

Citation: Sorscher S (2016) A First Case of Male Breast Cancer Responding to Combined Aromatase Inhibitor/Palbociclib Therapy. Int J Cancer Clin Res 3:069.



 Original Article 


Download PDF



View full article


Published Date
October 17, 2016

Vol. 3, Issue 7

Three-Dimensional Ultrasound: Is it Useful for Decision Making in the Management of Rectal Cancer? Is 3D Ultrasound Useful in Rectal Tumor?

Sthela M Murad-Regadas, Romulo M Almeida, Rosilma G Lima Barreto, Doryane MR Lima, Francisco Sergio Pinheiro Regadas, Lusmar Veras Rodrigues, Francisco Coracy C Monteiro, Paulo G Oliveira, Joao Batista Barreto and Univaldo Etsuo Sagae

Corresponding author: Sthela M Murad-Regadas, Associate Professor, Department of Surgery, Coordenator of Unit of Pelvic Floor and Anorectal Physiology, School of Medicine, Clinical Hospital, Federal University of Ceara; Department of Colorectal Surgery San Carlos Hospital, Fortaleza-CE, Av Pontes Vieira, 2551, Fortaleza, Ceara, 60130-241 Brazil

Consecutive patients treated for rectal cancer or adenomas in 4 colorectal centers in Brazil were included. Patients with early-stage rectal cancer identified by 3D-US were assigned to receive resection only, and those with a later stage were assigned to receive CRT. A second 3D-US was performed after CRT to detect the presence of residual tumor and metastatic lymph nodes or complete response.

Citation: Murad-Regadas SM, Almeida RM, Barreto RGL, Lima DMR, Regadas FSP, et al. (2016) Three-Dimensional Ultrasound: Is it Useful for Decision Making in the Management of Rectal Cancer? Is 3D Ultrasound Useful in Rectal Tumor? Int J Cancer Clin Res 3:068.



 Original Research Article 


Download PDF



View full article


Published Date
September 22, 2016

Vol. 3, Issue 7

Magnetic Resonance Imaging Targeted Biopsies alone are not Sufficient for Detection of Clinically Significant Prostate Cancer - A Systematic Review and Meta-Analysis

Cayce B Nawaf, Nathanial T Ondeck, Laura A Skrip, Rollin K Say, John M Gunselman, Jamil Syed, Peter G Schulam and Preston C Sprenkle

Corresponding author: Preston C Sprenkle, MD, Assistant Professor of Urology, Yale School of Medicine, New Haven, CT 06520-8058, USA

Magnetic resonance imaging targeted biopsies (MRI-Tbx) has the potential to detect significant prostate cancer with a small number of cores; however, there are concerns that some clinically significant (CS) cancers may not be visible on MRI or identified with targeted biopsies alone.

Citation: Nawaf CB, Ondeck NT, Skrip LA, Say RK, Gunselman JM, et al. (2016) Magnetic Resonance Imaging Targeted Biopsies alone are not Sufficient for Detection of Clinically Significant Prostate Cancer - A Systematic Review and Meta-Analysis. Int J Cancer Clin Res 3:067.



 Case Report 


Download PDF



View full article


Published Date
August 25, 2016

Vol. 3, Issue 6

Rapid Development of Type 1 Diabetes Mellitus after Initiation of Anti-PD-1 Therapy

Muneeb Shah, Luke Maxfield, Rehan Feroz and Kevin Donohue

Corresponding author: Muneeb Shah, College of Osteopathic Medicine, Nova Southeastern University, 3301 College Avenue, Fort Lauderdale, Florida 33314, USA

Programmed death protein 1 (PD-1) is a receptor on immune cells that serves as a checkpoint and plays an important role in preventing the activation of T-lymphocytes. Malignant cells are known to activate this receptor, thereby allowing them to evade immune surveillance. Programmed death 1 immune-checkpoint inhibitor antibodies (anti-PD-1), such as nivolumab, act to revamp the immune response against tumor cells by preventing activation of this PD-1 receptor.

Citation: Shah M, Maxfield L, Feroz R, Donohue K (2016) Rapid Development of Type 1 Diabetes Mellitus after Initiation of Anti-PD-1 Therapy. Int J Cancer Clin Res 3:066.



 Review Article 


Download PDF



View full article


Published Date
August 19, 2016

Vol. 3, Issue 6

Culture of Circulating Tumor Cells - Holy Grail and Big Challenge

Tianyu Guo, Claire S Wang, Wen Wang and Yongjie Lu

Corresponding author: Dr. Yong-Jie Lu, Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK

Circulating tumor cells (CTCs), the most important representation of 'liquid biopsy', provides a minimally invasive approach to tumor tissue, and has been a hot topic in cancer research for years. CTCs bear great potential to provide a surrogate for traditional biopsy, and the culture of CTCs is essential to investigate the biological features of CTCs and their roles in cancer metastasis as well as to provide the opportunity for in vitro therapeutic sensitivity tests to guild treatment selection.

Citation: Guo T, Wang CS, Wang W, Lu Y (2016) Culture of Circulating Tumor Cells - Holy Grail and Big Challenge. Int J Cancer Clin Res 3:065.



 Original Article 


Download PDF



View full article


Published Date
August 17, 2016

Vol. 3, Issue 6

Dosimetric Study on the Consequences of Replacing the mMLC Collimator Used for Intracranial SRS by an Integrated MLC-160

Tania Santos, Tiago Ventura, Miguel Capela and Maria do Carmo Lopes

Corresponding author: Tania Santos, Physics Department, University of Coimbra, Coimbra, Portugal, Rua Larga 3004-516 Coimbra, Portugal

At IPOCFG, stereotactic radiosurgery is performed using an add-on micro-multileaf collimator (3 mm minimum leaf width), m3, with full advanced integration in a linear accelerator equipped with a standard 82 leaf multileaf collimator with 1 cm leaf width. This work aimed to evaluate if it would be possible to dispense the use of the m3 if the standard MLC was replaced by a MLC-160 with 5 mm leaf width at isocenter.

Citation: Santos T, Ventura T, Capela M, Lopes MC (2016) Dosimetric Study on the Consequences of Replacing the mMLC Collimator Used for Intracranial SRS by an Integrated MLC-160. Int J Cancer Clin Res 3:064.



 Original Article 


Download PDF



View full article


Published Date
August 12, 2016

Vol. 3, Issue 6

Estimating Relapse Free Survival as a Net Probability: Regression Models and Graphical Representation. An Application of a Large Breast Cancer Case Series

Annalisa Orenti, Elia Biganzoli and Patrizia Boracchi

Corresponding author: Elia Biganzoli, Laboratory of Medical Statistics, Epidemiology and Biometry G. A. Maccacaro, Department of Clinical Sciences and Community Health, University of Milan, Italy

In most clinical studies, the evaluation of the effect of a therapy and the impact of prognostic factors is based on relapse-free survival. Relapse free is a net survival, since it is interpreted as the relapse-free probability that would be observed if all patients experienced relapse sooner or later. Death without evidence of relapse prevents the subsequent observation of relapse, acting in a semi-competing risks framework. Relapse free survival is often estimated by standard regression models after censoring times to death.

Citation: Orenti A, Biganzoli E, Boracchi P (2016) Estimating Relapse Free Survival as a Net Probability: Regression Models and Graphical Representation. An Application of a Large Breast Cancer Case Series. Int J Cancer Clin Res 3:063.



 Pilot Study 


Download PDF



View full article


Published Date
July 29, 2016

Vol. 3, Issue 6

Cancer Risk among Physicians is Different from that among Non-Physicians: An Observational Pilot Study

Hyun Young Kim

Corresponding author: Hyun Young Kim, MD, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea

We conducted a retrospective, case-control study on cancer risk among physicians and non-physicians at a health screening center. A total of 1,110 Korean subjects aged 30 to 65 years were assessed for cancer risk. A physician group (primary clinic, N = 147, tertiary hospital, N = 123) and non-physician group (N = 840) were included.

Citation: Kim HY (2016) Cancer Risk among Physicians is Different from that among Non-Physicians: An Observational Pilot Study. Int J Cancer Clin Res 3:062.



 Original Article 


Download PDF



View full article


Published Date
July 25, 2016

Vol. 3, Issue 5

Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer

Takeshi Kotake, Yuichiro Kikawa, Sachiko Takahara, Shigeru Tsuyuki, Hiroshi Yoshibayashi, Eiji Suzuki, Yoshio Moriguchi, Hiroyasu Yamashiro, Kazuhiko Yamagami, Hirofumi Suwa, Toshitaka Okuno, Takahito Okamura, Takashi Hashimoto, Hironori Kato, Akihito Tsuji and Masakazu Toi

Corresponding author: Takeshi Kotake, Breast Surgery Department, Kyoto University Hospital, 54, Shogoin-Kawaharacho, Sakyo-ku, Kyoto, Japan

Introduction: A multicenter observational retrospective study was conducted to assess the clinical response and survival impact, especially post-progression survival impact, of eribulin monotherapy in HER2-negative advanced or metastatic breast cancer (A/MBC) patients. Patients and methods: This retrospective observation cohort study contains 110 A/MBC patients treated with eribulin monotherapy during April 2011 and August 2014 in 12 Kyoto Breast Cancer Research Network (KBCRN) institutions.

Citation: Kotake T, Kikawa Y, Takahara S, Tsuyuki S, Yoshibayashi H, et al. (2016) Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer. Int J Cancer Clin Res 3:061.



 Case Report 


Download PDF



View full article


Published Date
June 29, 2016

Vol. 3, Issue 5

Rapid Fatal Progression of Cervical Cancer during Pregnancy Treated by Neoadjuvant Chemotherapy

Iptissem Naoura, Lise Selleret, Frederic Selle and Emile Darai

Corresponding author: Iptissem Naoura, Service de Gynecologie-obstetrique, Centre hospitalier universitaire Tenon, APHP, 4 rue de la Chine, 75020 Paris, France

Cervical cancer is the most commonly diagnosed gynaecological malignancy in pregnant women. The prognosis of this cancer does not seem to be influenced by the pregnancy. However, the cancer management comes into competition with maternal and foetal outcomes, especially during the 2nd trimester of pregnancy. Challenging issues lie in the cervical screening during pregnancy, the evaluation of lymph node status and the indication of neoadjuvant chemotherapy to avoid foetal prematurity without comprising maternal prognosis.

Citation: Naoura I, Selleret L, Selle F, Darai E (2016) Rapid Fatal Progression of Cervical Cancer during Pregnancy Treated by Neoadjuvant Chemotherapy. Int J Cancer Clin Res 3:060.



 Case Report 


Download PDF



View full article


Published Date
June 20, 2016

Vol. 3, Issue 5

Appendiceal Metastasis in a Patient with Advanced Breast Cancer on Hormonal Therapy

Edmond Kwan, Nezor Houli, Meron Pitcher and Shirley Wong

Corresponding author: Edmond Kwan, Medical Oncology Registrar, Western Health, Sunshine Campus, 176 Furlong Road, St Albans, VIC, Australia

A 70-year-old woman presented with abdominal pain nine months after the diagnosis of de-novo, hormonal-receptor positive advanced breast cancer. Imaging revealed appendiceal stranding likely representative of acute appendicitis. Surgery was performed, and pathological examination of the inflamed appendix revealed metastatic carcinoma consistent with breast primary. The case highlights the diagnostic challenges of abdominal pain in a patient with advanced cancer.

Citation: Kwan E, Houli N, Pitcher M, Wong S (2016) Appendiceal Metastasis in a Patient with Advanced Breast Cancer on Hormonal Therapy. Int J Cancer Clin Res 3:059.



 Mini Review 


Download PDF



View full article


Published Date
June 20, 2016

Vol. 3, Issue 5

ADAM17: A Gatekeeper in Immune-Oncology?

Peter R Lowe and Nathalie Corvaia

Corresponding author: Peter R Lowe, Department of mAbOptimization, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoleon III, 74160, St Julien en Genevois, France

Recent therapeutics searching to reactivate and target the immune system to destroy tumors have demonstrated remarkable success in the treatment of patients with previously intractable disease such as metastatic melanoma. Current research is enlarging the spectrum of targets and strategies for enhancing the immune response against tumors, in order to further improve treatment efficacy. In that respect, ADAM17, has frequently been described for it's over expression or over activation in the tumor microenvironment. ADAM17 is responsible for the shedding of a large number of receptors and ligands involved in immune tumor targeting and the deregulation of this activity should be considered when developing therapeutic strategies.

Citation: Lowe PR, Corvaia N (2016) ADAM17: A Gatekeeper in Immune-Oncology? Int J Cancer Clin Res 3:058.



 Review Article 


Download PDF



View full article


Published Date
June 13, 2016

Vol. 3, Issue 5

Immune and Genetic Susceptibility in the Development of Cervical Cancer

Barbara Mora, Felipe M Benavente, Carmen G Ili and Priscilla Brebi

Corresponding author: Priscilla Brebi, Department of Pathology, Molecular Pathology Laboratory, School of Medicine, Universidad de La Frontera, Av Alemania 0458, Temuco, Chile

Cervical cancer is the second most frequent cancer in women worldwide. Although 99.7% of cases are attributed to a previous infection by Human papillomavirus, a small percentage of the infected women progress to cervical cancer, suggesting the existence of different risk factors involved in the development and progression of this pathology. Genetic variability related to the host immune system could play an important role in the defense response to Human papillomavirus and therefore to the probability of developing cervical cancer. Worldwide, several international studies have reported that some genetic variations in immune system, such as polymorphisms in genes HLA, CTLA-4, MTHFR, Tp53 and receptors of natural killer cells are associated with susceptibility to cervical cancer, although these variations can also play a protective role depending on the study population. The role of the genetic factors of the host cell is an important factor in the progression of the cervical cancer.

Citation: Mora B, Benavente FM, Ili CG, Brebi P (2016) Immune and Genetic Susceptibility in the Development of Cervical Cancer. Int J Cancer Clin Res 3:057.



International Journal of Anesthetics and Anesthesiology (ISSN: 2377-4630)
International Journal of Blood Research and Disorders   (ISSN: 2469-5696)
International Journal of Brain Disorders and Treatment (ISSN: 2469-5866)
International Journal of Cancer and Clinical Research (ISSN: 2378-3419)
International Journal of Clinical Cardiology (ISSN: 2469-5696)
Journal of Clinical Gastroenterology and Treatment (ISSN: 2469-584X)
Clinical Medical Reviews and Case Reports (ISSN: 2378-3656)
Journal of Dermatology Research and Therapy (ISSN: 2469-5750)
International Journal of Diabetes and Clinical Research (ISSN: 2377-3634)
Journal of Family Medicine and Disease Prevention (ISSN: 2469-5793)
Journal of Genetics and Genome Research (ISSN: 2378-3648)
Journal of Geriatric Medicine and Gerontology (ISSN: 2469-5858)
International Journal of Immunology and Immunotherapy (ISSN: 2378-3672)
International Journal of Medical Nano Research (ISSN: 2378-3664)
International Journal of Neurology and Neurotherapy (ISSN: 2378-3001)
International Archives of Nursing and Health Care (ISSN: 2469-5823)
International Journal of Ophthalmology and Clinical Research (ISSN: 2378-346X)
International Journal of Oral and Dental Health (ISSN: 2469-5734)
International Journal of Pathology and Clinical Research (ISSN: 2469-5807)
International Journal of Pediatric Research (ISSN: 2469-5769)
International Journal of Respiratory and Pulmonary Medicine (ISSN: 2378-3516)
Journal of Rheumatic Diseases and Treatment (ISSN: 2469-5726)
International Journal of Sports and Exercise Medicine (ISSN: 2469-5718)
International Journal of Stem Cell Research & Therapy (ISSN: 2469-570X)
International Journal of Surgery Research and Practice (ISSN: 2378-3397)
Trauma Cases and Reviews (ISSN: 2469-5777)
International Archives of Urology and Complications (ISSN: 2469-5742)
International Journal of Virology and AIDS (ISSN: 2469-567X)
More Journals

Contact Us

ClinMed International Library | Science Resource Online LLC
113 Barksdale Professional Center, Newark, DE 19711, USA
Email: contact@clinmedlib.org
Tel: +1-302-294-0935  

Feedback

Get Email alerts
 
Creative Commons License
Open Access
by ClinMed International Library is licensed under a Creative Commons Attribution 4.0 International License based on a work at http://clinmedjournals.org/.
Copyright © 2014-2015, All Rights Reserved ClinMed International Library, Science Resource Online LLC
| Best Viewed in Mozilla Firefox and Chrome |